Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Thermalin Diabetes

Request full access

Developing next-generation, heat-stable, and rapid-acting insulin analogs

Cleveland, United StatesFounded 2007Biotech & Life Sciences

About Thermalin Diabetes

Thermalin Diabetes, LLC is a biotechnology firm founded in 2007, operating out of Cleveland, Ohio. The company focuses on developing a portfolio of next-generation insulin analogs to address unmet needs in the diabetes market. Its product pipeline includes ultra-stable insulins that do not require refrigeration, ultra-rapid absorbing insulins for artificial pancreas systems, ultra-concentrated formulas for miniaturized insulin pumps, and liver-focused insulins for active diabetic patients.

The company was founded by Dr. Michael A. Weiss, a distinguished researcher from Case Western Reserve University (CWRU) School of Medicine, who has studied insulin for over three decades. His scientific work on engineering new insulin molecules forms the basis of the company's intellectual property, which is exclusively licensed from CWRU. The business side was initially led by CEO Rick Berenson, a serial entrepreneur and a former Harvard undergraduate roommate of Dr. Weiss. The company's business model revolves around research and development, with the goal of forming strategic partnerships with large pharmaceutical companies for clinical development and commercialization. A significant milestone was a major collaboration with Sanofi announced in 2017 to discover and develop novel insulin therapies, which included a Series A financing round of at least $17.5 million.

Thermalin has secured substantial funding through multiple rounds, raising over $56 million from investors like Sanofi, Jumpstart, and JSR・mblVC LifeScience Investment Limited Partnership, in addition to grants from the National Institutes of Health (NIH). The company's strategy is to create superior insulin products that are faster-acting, longer-lasting, more concentrated, and more stable than existing options, aiming to reduce the burden of insulin therapy, improve patient adherence, and enhance safety.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
25.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Personal Health, Diabetes, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing Aug 2022 $0 — Robin Hood Ventures —
CONVERTIBLEEquity / VC Sep 2020 $45K — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Thermalin Diabetes website traffic

Latest recorded traffic for Thermalin Diabetes is 250 monthly website visits, down 55.4% over the last three months. Thermalin Diabetes's team grew 0% over the past year.

Latest monthly visits250 3-month web change-55.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Thermalin Diabetes in the Cleveland ecosystem

Live from Dealroom

The Thermalin Diabetes office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • JumpStart Ventures
  • U.S. Small Business Administration
  • US Department of Health and Human Services
  • National Institutes of Health

Series A3 investors entered at this stage

  • Sanofi
  • Green Park & Golf Ventures
  • JumpStart

Other known investors7 additional known investors

  • Case Western Reserve University
  • Robin Hood Ventures
  • Innovation Fund Northeast Ohio
  • Kensington Capital Holdings
  • Mass Medical Angels
  • Mid Atlantic Bio Angels
  • Small Business Innovation Research
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States83.3%
🇫🇷 France16.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Thermalin Diabetes on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Thermalin Diabetes’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.